Diagnostic test kit maker Meridian Bioscience (VIVO) has won the approval of the U.S. Food and Drug Administration (:FDA) for its new test for detection of Legionnaire’s disease (legionellosis), a ...
Meridian Bioscience has filed an application for federal regulatory approval of a next-generation molecular test that detects a type of bacteria that causes damage to the digestive system. Meridian’s ...
illumigene® Malaria is more widely used than it was a year ago, but Meridian Bioscience says even more countries should use it." Researchers in Europe and philanthropists in New York are singing the ...
Meridian Bioscience Inc. (NASDAQ:VIVO) has obtained a license to begin selling its illumigene C. difficile molecular test in Canada. C. difficile is a bacterium that can cause symptoms ranging from ...
Newtown-based Meridian Bioscience is deploying its newly developed test illumigene® Malaria in Dakar, Senegal and planning a rollout of this potentially life-saving diagnostic across Africa. A test ...
Meridian Bioscience Inc (NASDAQ: VIVO) has agreed to acquire the North American BreathTek business from Otsuka America Pharmaceutical Inc for $20 million in cash. The transaction will close in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results